DC control is important to vitreous flow

Article

The variable duty cycle (DC) control on dual pneumatic ultra high-speed 23G cutters has an important effect on the vitreous flow but this is reduced at high cut rates as a result of convergence, reveals a paper in Retina.

The variable duty cycle (DC) control on dual pneumatic ultra high-speed 23G cutters has an important effect on the vitreous flow but this is reduced at high cut rates as a result of convergence, reveals a paper in Retina.

Dr Bruno Diniz et al., Doheny Eye Institute, Los Angeles, California, USA, used frame-by-frame analysis of high-speed video to determine the DC in core, 50-50 and shave modes. The team used three cutters at various cycles per minute and aspiration levels, mass of water or vitreous removed from a vial was recorded within a certain time period.

For all three modes the DC converged at 5000 cycles per minute and water flow curves followed the DC variation. Vitreous flow rates for all DC modes increased along with the cut rates and peaked at 5000 cycles per minute. Vitreous flow rate independently increased when the DC influence was isolated and aspiration or the cut rate was increased.

Both progressive aspiration value and cut rate, either together or independently, increase the vitreous flow irrespective of the DC. Also, high cut rates reduce the significant effect the DC control has on the vitreous flow.

Please follow this link to read the abstract.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.